Azure Synthetics Azure Synthetics Research peptides, clearly documented.
DE
Warenkorb 0 Browse catalog
Retatrutide

Metabolic research

Retatrutide

Lyophilized metabolic research compound

Retatrutide is a metabolic research peptide studied as a triple agonist at GIP, GLP-1, and glucagon receptors. Published studies provide receptor-pharmacology and dose-ranging context for this molecular class.

Preisspanne: 124.99 $ bis 1,062.99 $
98.5%-99.2% Lyophilisiertes Pulver 15 mg
Available certificate of analysis

This product has an available COA with reported batch details and test results.

Open available COA

Nur für Laborforschungszwecke. Nicht für den menschlichen oder veterinärmedizinischen Gebrauch bestimmt. Nicht zur Diagnose, Behandlung, Heilung, Linderung oder Vorbeugung von Krankheiten bestimmt.

Lagerung

Verschlossen, kalt, trocken und vor Hitzeschwankungen geschützt aufbewahren. Bestätigen Sie die produktspezifische Lagerung bei der Ankunft.

Versandhinweise

Verpackt für Transportstabilität mit Bestellunterstützung für Routen bei warmem Wetter.

Batch reference

Batch-linked certificate support is available through the documentation desk.

Forschungskontext

Retatrutide Forschungsprofil

Retatrutide is studied as a single peptide with agonist activity at the GIP, GLP-1, and glucagon receptors. Research commonly compares receptor potency, signaling balance, pharmacokinetics, glucose and lipid markers, energy expenditure, and body-mass endpoints across cell, animal, and controlled human studies. Its main distinction is the addition of glucagon-receptor activity to the incretin pathways represented by GIP and GLP-1. This makes it useful when a project needs a triple-agonist reference rather than the dual-receptor profile associated with tirzepatide. Published human trial results describe the investigated pharmaceutical molecule and do not establish the identity or performance of a catalog batch.

Vorgeschlagener Mechanismus

Proposed triple agonism at the GIP, GLP-1, and glucagon receptors. GIPR and GLP-1R signaling is associated with glucose-dependent insulin secretion and appetite-related pathways, while GCGR activity adds hepatic and energy-expenditure signaling. The balance of activity across all three receptors is central to the molecule.

In Studien berichtete Effekte

  • Cell and animal studies report activation of all three receptor pathways, reduced food intake, improved glucose handling, and increased energy expenditure.
  • Phase 2 human studies reported dose-dependent reductions in body weight and improvements in selected cardiometabolic markers.
  • Gastrointestinal adverse events and treatment discontinuations were also reported in controlled human studies.

Häufige Forschungsendpunkte

Receptor potency and bias, cyclic AMP response, food intake, energy expenditure, glucose and insulin markers, lipids, body mass, pharmacokinetics, and tolerability observations.

Evidenz und Grenzen

Mechanistic, animal, and controlled human evidence exists for the investigational pharmaceutical molecule. Those results do not verify a separate catalog batch or guarantee an experimental result.

External reading

Literature for context—not product proof.

Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.

Support and documentation

Questions about this product?

What documentation can I request before ordering?

Open the available COA on this page. Before ordering, confirm the named material and listed format; when the order arrives, match the document identifiers to the supplied lot.

What should I confirm before ordering?

Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.

Keep comparing

Compare other catalog records.

Explore related research materials. These are not a combined-use recommendation.